Laserblood: a new hope
Biomedical research has long aimed to cure cancer, leveraging advanced technologies and drugs to enhance survival rates. However, cancer remains a global burden due to limited accessibility and high costs of treatments. Tumor prevention emerges as a vital approach to combat cancer, potentially reducing mortality rates and healthcare expenses. Unfortunately, effective screening methods are lacking for many cancer types, including pancreatic ductal adenocarcinoma (PDAC), which exhibits a dismal five-year survival rate of less than 10%. Laserblood, a research initiative funded by the European Commission’s EIC Pathfinder program, offers hope for PDAC prevention. Led by FLIM LABS, Laserblood utilizes Fluorescence Lifetime Analysis (FLA) to identify PDAC markers in blood samples, enabling early diagnosis and treatment evaluation. Collaborating with esteemed institutions, Laserblood aims to develop a non-invasive in vitro diagnostic test, leveraging FLIM LABS’ innovative technology to combat this lethal cancer effectively.
Focus on Microscopy 2024
Vieni a conoscere la tecnologia Flim labs e a discutere con noi di Fluorescence Lifetime Analysis e Fuorescence Lifetime Imaging Microscopy, al FOM 2024 a Genova dal 24 al 27 Marzo
contattaci +39347942823 info@m-s.it
